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1. Introduction 
In the real world, there is an important step before seeing the effects and the outcome of 
cancer treatment. This step is to see that treatment become accessible and affordable for 
cancer patients. The rapidly increasing of costs of novel cancer drugs and radiation therapy 
equipment doesn`t commensurate with the slowly improvement of outcome. Thus, each 
advance in treatment, the magnitude of the increase in the cost of treatment exceeded the 
magnitude of improvement of efficacy. (Schrag, 2004). Pharmaceutical companies are 
developing costly novel cancer drugs that are marketed in the USA, Western Europe, and 
Japan with fewer markets and opportunities in Low and Middle Income Countries (LMICs). 
By the year 2020, among the 20 million new cancer cases, 70% will be located in the 
countries that have collectively, just 5% of the global cancer control resources. (Ferlay et al, 
2010, Porter et al., 1999 & Stewart & Kleihues, 2003). At present, it is roughly estimated that 
at least half of cancer patients in the world have no access to cancer therapy. This situation is 
particularly marked –with variability – in LMICs. The problem is particularly tragic for 
Radiotherapy in sub- Saharan Africa where only 5% of cancer patients have access to 
radiotherapy (Elzawawy, 2008, Porter et, 1999). However, there are also variable 
proportions of cancer patients in high income countries like the USA who have difficulties 
in obtaining expensive cancer drug treatment and radiotherapy. (Bach, 2007 & Malin, 2010). 
There is no indication that the costs of these drugs will diminish in the future in the USA 
(Meropol & Schulman, 2007).  
In the next decade, with the expected increase of numbers of cancer patients particularly in 
LMICs and with the increasing costs of treatment with novel drugs and radiation therapy 
particularly in LMICs, then, this situation would be aggravated and it could present more 
difficulties for all stakeholders; cancer patients, oncologists, health policy makers and 
governments, manufactures of cancer drugs and radiotherapy equipment and economists. 
This could cause difficulties for the wheel of advances in treatment and science and in 
marketing of innovation. Hence, a pressing need emerges for scientific initiatives. One of the 
recent scientific initiatives, in which most of representatives of the key international 
organizations are sharing in its meetings and development, is The Win-Win Scientific 
initiative that was proposed first by ICEDOC’s Experts in Cancer without borders on 
December 2007. (ICEDOC is The International Campaign for Establishment and 
Development of Oncology Centers. www.icedoc.org). Breast Cancer is the most frequent 
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malignancy among females with about 1.4 million cases annually in the world. Multiple 
treatment modalities and drugs are used in its management (Ferlay et al, 2010 & Stewart & 
Kleihues, 2003). The present chapter focuses on updating the exploration of examples of the 
published and ongoing scientific researches and approaches that could lead to resource 
sparing and cost effective radiotherapy, chemotherapy and hormonal treatment of breast 
cancer as a model that could be expanded to other cancers in the world. Despite of all 
difficult challenges and the expected increase of problems of affordability and marketing of 
increasingly expensive cancer treatment, we aim at developing win-win scientifically based 
initiative and scenarios in which the interests of the main stakeholders are really considered. 
We stress on the notions of not compromising the overall outcome of treatment and to pay 
attention to the ways of its assessment in different parts of the world. North-North, North-
South and South-South scientific collaboration are warranted in order that more cancer 
patients in the world would have access to cost effective treatment tailored to realistic 
conditions of each community.  
2. Resource sparing in radiotherapy for breast cancer 
2.1 Postoperative – post mastectomy and post lumpectomy – radiotherapy of breast 
cancer 
2.1.1 Altered fraction schedules 
2.1.1.1 Shorten fractionation for postoperative radiotherapy (Hypofractionation) 
An example is The UK standardization of breast radiotherapy (START) randomized trial B. 
Between 1999 and 2001, 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 
centers in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 
fractions of 20 Gy over 5 weeks or 40 Gy in 15 fractions of 267 Gy over 3 weeks. Women 
were eligible for the trial if they were aged over 18 years, did not have an immediate 
reconstruction, and were available for follow-up. Randomization method was computer 
generated and was not blinded. The protocol specified principal endpoints were local-
regional tumor relapse, defined as reappearance of cancer at irradiated sites, late normal 
tissue effects, and quality of life. Analysis was by intention to treat. This study is registered 
as an International Standard Randomized Controlled Trial, number ISRCTN59368779. The 
study showed that the radiation schedule delivering 40 Gy in 15 fractions offer rates of local-
regional relapse and adverse effects at least as favorable as the standard of 50 Gy in 25 
fractions (The START Trialists' Group, 2008). However, it is critical to realize that the late 
effects produced by RT are strongly related to dose per fraction. Therefore, higher dose per 
fraction increases the susceptibility of normal tissues to RT. It is for this reason that the data 
on late lung and cardiac morbidity and survival rates is very important when 
hypofractionated regimens are employed in breast cancer. The Oxford meta-analysis has 
reported that RT reduced the annual mortality from breast cancer by 13% but increased the 
annual mortality rate from other causes by 21%. Also, this increase was due primarily to an 
excess number of deaths from cardiovascular causes (Early Breast Cancer Trialists' 
Collaborative Group, 2000). By radiobiological rationale, hypofractionation has the potential 
for worsening cardiovascular side effects. Furthermore, the cardiac side effects take up to 15 
years to manifest completely after treatment and persist well beyond this period (Munshi A. 
2007). The hypofractionation in post mastectomy or lumpectomy radiotherapy has not been 
applied in the vast majority of centers in the world. This strategy will however be watched 
with keen interest since it has the potential to drastically reduce treatment times and has 
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important financial implications. (Munshi, 2009). There is a midway solution that could be 
also reasonable particularly for LMICs; the fractionation of 45 Gy in 18 fractions –used in 
Port Said, Egypt- which is adopted from the fractionations practiced successfully along 
years since the seventieth in many French centers (Sarrazin et al., 1989)  
2.1.1.2 Accelerated partial breast irradiation (APBI)  
Although hailed as a paradigm shift, the breast conservative treatment that emerged in 
the 1980s was in fact an extension of the Halstedian concept, wherein whole-breast 
irradiation (WBI) compensated for the limited surgery. Observations that 80-90% of breast 
recurrences after breast conservative surgery and WBI occur in the tumor bed questions 
the need for protracted elective WBI, and provides the rationale for accelerated-partial-
breast irradiation (APBI) of small cancers without adverse features predisposing to 
multicenteric recurrence. APBI would mark a paradigm shift and a major advance in 
treatment. This would allow many more women to opt for breast conservation, resolve 
the dilemmas regarding chemotherapy and radiotherapy sequencing and perhaps would 
be more cost effective. (Sarin, 2005). Several techniques including multicatheter interstitial 
brachytherapy, intracavitary brachytherapy, intraoperative radiation therapy, and 3D 
conformal external beam radiation therapy have been proposed, and each of them has its 
own advantages and drawbacks. Although APBI is increasingly used in the United States 
and Europe, and the short-term results are promising, its equivalence with whole breast 
radiation therapy is not fully established. In addition, because the average breast size in 
some countries like Japan is considerably smaller than in the West world, the application 
of APBI to Japanese patients is technically more challenging. At this point, APBI is still an 
investigational treatment in Japan, and the optimal method of radiation delivery as well 
as its long-term efficacy and safety should be clarified in clinical trials (Mitsumori & 
Hiraoka, 2008). Our point of view is that in LMICs, breast cancer cases are usually more 
advanced than in the West and the price of machines would be expensive. However, we 
suggest thinking about the manufacture of a low cost 50 KV Radiotherapy machines 
adapted for the use in some middle income countries and that could be used for some 
other indications too.  
2.1.1.3 Concurrent boost radiotherapy (CBRT) during the course of whole-breast 
radiotherapy (WBRT)  
It implies giving boost radiotherapy concurrently during the course of WBRT itself 
instead of giving it sequentially after WBRT. There are different ways to deliver CBRT. A 
study was done to shorten the relatively long duration of treatment by delivering a 
concomitant boost (CB) to the tumor bed on Saturdays (Jalali et al., 2007). Thirty patients 
with locally advanced breast cancers suitable for breast conservation following 
neoadjuvant doxorubicin / epirubicin chemotherapy (CAF/CEF) were accrued in the 
study. Conventional RT (CRT) to the whole breast was delivered 5 days a week to a dose 
of 50 Gy, using 6-10 MV photons. In addition, an electron boost to the tumor bed was 
delivered every Saturday (12.5 Gy/5 fractions, weekly fraction on Saturday). With this, 
the entire RT treatment was completed in 5 weeks instead of the usual 6 weeks. All 
patients completed RT within the stipulated time with no grade IV skin toxicity in either 
group. CB did not significantly affect the global cosmetic results as compared with the 
CRT group at the end of 3 years (P=0.23). In another study, 52 patients with early-stage 
node-negative breast cancer were enrolled. The RT dose to the whole breast was 40.5 Gy 
in 2.7 Gy/fraction with a CB of 4.5 Gy in 0.3 Gy/fraction. With this, the entire RT 
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treatment was completed in 3 weeks No acute Clinical toxicity criteria (CTC) grade III or 
IV and no late soft tissue toxicity were noted. The cosmetic results observed were good to 
excellent. (Chadha et al., 2007). These studies demonstrate that giving a CB during whole-
breast RT is a viable resource-sparing option and does not lead to any detriment in local 
control and cosmetic outcome. (Munshi. 2009) 
2.1.2 Less number of radiation fields 
Since systemic adjuvant therapy is given to most patients today, the traditional 
radiotherapy technique has been modified, many authors no longer recommended that 
patients who have undergone complete or level I/II axillary dissections should receive 
full axillary radiotherapy since survival is not improved and the risk of lymhoedema is 
increased. Also, the isolated internal mammary chain failure is rare even when 
radiotherapy is not given (Truong et al., 2004). However, still areas of controvert exist 
regarding irradiation of the regional lymph nodes (Axillary, supraclavicular and internal 
mammary lymph nodes). The Applied Radiation Biology and Radiotherapy (ARBR) 
Section of the Division of Human Health, International Atomic Energy Agency (IAEA), 
pays great attention to resource sparing strategies in cancer radiotherapy. One of the on-
going important multicentre randomized studies is about resource sparing in breast 
cancer treatment. It is started in the year 2007. This study is comparing irradiation of the 
chest-wall only versus irradiation of the chest-wall and the supraclavicular field in 
patients who underwent a mastectomy. In addition, the ARBR Section is conducting 
clinical trials in cervical cancer, oesophagus, lung, rectal, glioblastoma multiforme, 
nasopharyngeal cancer and painful bone metastasis. 
2.2 Palliative radiotherapy of painful bone metastasis  
2.2.1 Single versus multiple fractions  
Radiotherapy remains the main modality of management for symptomatic bone metastases. 
The goal of radiotherapy in such cases is to provide pain relief and optimization of quality 
of life (QoL) with minimal displacement, discomfort, hospitalization, morbidity for patients 
and minimal cost and time commitment as well. Performance status and degree of systemic 
disease must be considered prior to treatment. (Janjan et al., 2009 & Fairchild & Stephen, 
2011). Approximately 25 randomized clinical trials and three meta–analysis have 
demonstrated equivalency of single and multiple fraction radiotherapy for bone relief from 
uncomplicated bone metastases. Other advantages of single fraction include decreased cost 
and lower risk of acute effects (Chow et al., 2007). The single fraction is preferred when 
examining the cost utility, but there is higher rate of retreatment associated with single-
fraction radiotherapy (Van den Hout et al, 2003). In a randomized clinical trial with two 
palliative radiotherapy regimens 8 Gy/I fraction versus 30 Gy/10 fractions, the overall 
responses were 75% and 86% successively while the rate of re-treatment were 28% and 2% 
successively. (Foro et al, 2008). Similar results were obtained from a prospective randomized 
multi centeric trial in which the total number of patients was 376. The rate of re-treatment 
(15%) was also higher in the group of Single 8 fraction than the rate of retreatment (4%) in 
the group treated with 30 Gy/10 Fractions. (Kaasa et al. 2006). However, most authors 
recommend multiple fractionations for primary treatment of complicated bone metastases 
for which there is no surgical option, or for postoperative treatment. The goals of 
postoperative radiation therapy are to decrease pain, promote healing and minimize the risk 
of progression (Fairchild & Stephen, 2011). 
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It is worthwhile to note that the treatment of asymptomatic bone metastases may deferred 
unless the patient is at risk of a serious adverse outcome such as spinal cord compression or 
impending pathological fracture (Janjan et al., 2009).  
2.2.2 Half-body irradiation  
Retrospective and prospective phase I and II studies suggest that single dose (6-8 Gy) 
hemibody irradiation provides pain relief in 70-80% of patients with multiple sites painful 
metastases. Studies also report decreased opioid use and need for localized external beam 
radiotherapy. Patients should be premedicated with intravenous fluid, antiemetics, 
corticosteroids and analgesics in case pain flare. Sequential treatment of both upper and 
lower Hemibody Irradiation requires a 6 weeks gap for recovery of myelosuppresion. 
(Fairchild & Stephen, 2011)  
2.2.3 The follow up of radiotherapy of bone metastases 
According to the International bone metastases consensus working party recommendation, 
the determination of response is clinical, thus biochemical or imaging studies -with 
subsequent costs- are not routinely required in follow up. (Chow et al., 2002). 
2.3 General measures 
These could be done by the local professionals and health authorities or in consultation with 
regional and/or international institutions and organizations particularly The International 
Atomic Energy Agency (IAEA) and its Applied Radiation Biology and Radiotherapy Section 
(ARBR) and The Program of Action for Cancer Therapy (PACT). These include: 
2.3.1 General strategic planning of radiotherapy facilities in developing countries 
In a Consultation to the World Health Organization, a global strategy for Radiotherapy was 
proposed. It considered different local parameters including the Gross National Product 
GNP per Capita that categorized countries in the world into 4 groups (Levels). Accordingly 
series of three tier radiotherapy service was proposed, with internet-based 
intercommunication strategy (Porter et al., 1999). One of the interesting proposal that goes 
with the three tier system is the creation of an integrated three-tier radiotherapy service, 
which consists of primary, secondary, and tertiary radiotherapy centres in developing 
countries—coordinated through a teleradiotherapy network. Such a network could be cost 
effective, help to bridge the gap, and give all patients access to the state-of-the-art 
technology in radiotherapy (Datta & Rajasekar, 2004). The Breast Health Global Initiative 
(BHGI), suggested four levels for availability breast cancer management; Basic, Limited, 
Enhanced and Maximal (Anderson et al., 2006, Anderson & Cazap, 2009 & Bese et al., 2008). 
2.3.2 Practical modifications of the system of work in radiotherapy departments 
These are in order treat more numbers of patients, like to increase the hour work of cobalt 
machines in developing countries, the increase the number of fractions a week from 5 to be 6 
fractions in certain applications (Overgaard et al., 2006), the reduction of Machine down-
time in many developing country institutions that is mainly due to problems of maintenance 
and lack of culture of local regular preventive maintenance (Bhadrasain, 2005). In our view, 
we emphasizes on the importance of programs that should developed in order to assure 
that most of the problems of down-time of machines would be fixed in the soonest as 
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possible by the local teams either solely or and with prompt telecommunication with 
manufcturer maintenance staff. 
2.3.3 Professional training 
Customized and regular updating training are recommended for the local medical and 
technical staff and maintainers (Bhadrasain, 2005 &Porter et al., 1999). This because the local 
staff -and not the sophistication in machines- are the back bone of resource sparing and 
successful cost effective treatment for more number of patients. 
2.4 Future directions regarding radiotherapy  
From the above cited points and examples, and by rough estimation, and without additional 
high resources, the number of breast cancer patients treated by the present existing facilities 
of radiotherapy could be nearly doubled particularly in middle income countries. This could 
increase the cost-effectiveness of radiotherapy in the world and hopefully would be a 
stimulus for increasing facilities of radiotherapy in the world.  
It is estimated that at least 5,000 additional radiotherapy machines are presently needed 
worldwide and, by 2015, at least 10,000 radiotherapy machines may be needed to meet 
growing treatment demand. It is estimated that during the upcoming 20-year,it is estimated 
that 100 million cancer victims in the developing countries will require radiotherapy, for 
cure or the relief of symptoms such as pain and bleeding. Sadly, only 20-25% of patients in 
developing countries that need radiotherapy can access it today, and the situation will only 
worsen in the future unless steps are taken to address it (Bhadrasain, 2005 & Yip, 2011).  
In a recent study done in the US, only 77.6% of breast cancer patients received RT among the 
135 patients undergoing mastectomy with strong indications. One of the causes of not 
receiving radiotherapy is the socio-economic condition (Jagsi et al.,2010). Hence, even in the 
US there are disparities in access to radiotherapy, but, surely it is not comparable with the 
situation in LMICs. In well-developed countries today, around one-half of the cancer 
patients require radiotherapy. In developing countries, however, an even greater proportion 
require radiotherapy due to the location and relatively advanced stages at presentation of 
many common cancers, which precludes adequate treatment by surgery alone (Bhadrasain, 
2005 & Porter et al. 1999). Contrary to belief, radiotherapy is a cost-effective and not that 
expensive, it is salient to note that the cost of one military jet would represents the entire 
costs of radiotherapy for a country in some of parts of the world (Porter et. al. 1999).  
Developing countries should evolve their own evidence-based guidelines and cost sparing 
in cancer treatment. For example, chemo-radiation of solid tumors in the nutritionally 
deprived patient may not accrue the same level of benefit as seen in the literature from 
affluent countries Clinical trials conducted in developing countries can most appropriately 
address these important questions in a scientifically robust manner. Ideas for such studies 
are always welcomed, even from individuals. Clinical investigators from developing 
countries are the key to appropriately addressing those challenges, by the rational 
utilization of radiotherapy and allied technologies - both new and old (Bhadrasain, 2005). 
Furthermore, The PACT/IAEA has formed recently an Advisory Group for Increasing 
Access to Radiation Therapy in Developing Countries (AGaRT), that includes international 
experts from organizations, national representatives and in collaboration with 
manufactures. ICEDOC is represented in this promising effort of PACT that -hopefully- if 
the international will, science and the interests of stakeholders including the manufacturers 
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come together in a win-win environment to achieve feasible objectives, then, it could be a 
turning point in the history of affordability of Radiotherapy of cancer in many underserved 
regions in the world. 
3. Cost sparing in Breast Cancer Systemic Therapy (BCST) 
In reviewing the current literature, we provide examples of innovative ideas, evidence-
based approaches, and ongoing efforts that could decrease costs of BCST without 
compromising outcomes.  
3.1 Relatively recent and expensive drugs 
3.1.1 Evidence based cost effective indications of drugs 
An example is the limitation of the use of Trastuzumab in breast cancer to women with 
non-metastatic disease and known HER2/neu positive status (Yarney et al., 2008). 
Limiting the use of Trastuzumab to women with ERBB2 positive status is cost effective 
measure, even with the additional associated cost of the test (de Sousa & Bines, 2009). 
Nevertheless, in the United States, a recent study revealed that up to 20% of patients 
receiving Trastuzumab were never tested nor had any documentation of a positive test 
result (Phillips et al, 2009). 
3.1.2 Shorter course of treatment 
An example is the shorter course of trastuzumab. The optimal duration of adjuvant 
trastuzumab therapy remains undetermined. There are trials in progress comparing 52 
weeks of trastuzumab with 9 weeks, 3 months and 6 months. The FinHer (Finland 
Herceptin) study indicated that a 9-week period of trastuzumab administration is effective 
in women with HER2/neu-positive breast cancer. This means saving of around 80-90% of 
the cost of longer course (Joensuu et al., 2009). This is in addition to less total time of 
hospitalization, less risks of cardiac toxicities due to trastuzumab and less cost of the 
subsequent supportive treatment due to longer courses. 
3.1.3 Pharmacokinetic studies to lower the dose by changing regimen of infusion 
This is based on application of the pharmacological information and how the drug is 
transformed to its active ingredient in the body. An example is the low dose, prolonged 
infusion of gemcitabine. Hence, the habitual dose of 1000-1250 mg/m2 for one patient could 
be enough for 4-5 patients. Phase I–II trials of low dose gemcitabine in prolonged infusion 
(of 250 mg and 180 mg/m2 for 6 and 24 h, respectively) and its comparable results in 
responding solid cancers like non-small cell lung cancer, breast, pancreas, and bladder 
cancers are encouraging. The explanation lies in the saturation of the enzyme deoxcytidine 
kinase needed for conversion of gemcitabine into its active form gemcitabine triphosphate, 
which occurs after short conventional infusion and leaves most of the drug unmetabolized 
(Zwitter et. al, 2005 & Khaled et al, 2008).  
3.1.4 Dugs interactions and pharmacokinetic based studies  
Lapatinib is an oral dual tyrosine kinase inhibitor of both epidermal growth factor receptor 
and ERBB2, approved for advanced ERBB2-positive breast cancer after failure of 
trastuzumab treatment. Pharmacokinetic-based studies include the example that showed 
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that lapatinib taken orally with food and beverage containing CYP3A such as grapefruit 
juice, and not on an empty stomach as stated on the label, results in increased plasma levels 
and could reduce the dose and costs of lapatinib by 80%. Hence, for this expensive drug the 
habitual dose for one patient which is around 1250-1500 mg per day, could be enough for 
five patients, in addition to save cost of treatment of diarrhea due to lapatinib. It was 
suggested that the diarrhea is caused by the unabsorbed drug in the gut (Ratain and Cohen, 
2007). Pharmacokinetic studies that pursue ways to enhance bioavailability of agents could 
markedly decrease the required doses and subsequent cost of treatment. Strategies include 
the support of clinical trial processes to pursue evidence to support less costly and optimal 
therapeutic efficacy outcomes (Elzawawy, 2008 & 2009). 
3.1.5 Interrupted courses 
Potential research questions include the interrupted courses of Aromatase inhibitors (AI) 
that probably would be also effective as continuous therapy after prior Tamoxifen and/or 
AI treatment. The hypothesis is that AI interrupted courses perhaps could enhance response 
of residual resistant cells (Colleoni and Maibach, 2007). This area is still in need for more 
researches. It could be the occasion to cite another example in another cancer i.e. prostate 
cancer, with different hypothesis. In a phase III randomized trial comparing intermittent 
androgen suppression IAS versus continuous androgen suppression for patients with PSA 
progression after radical radiotherapy. IAS was delivered for 8 months in each cycle with 
restart when PSA reached >10 ng/ml off treatment. Overall survival (OS) was not inferior in 
the arm of IAS, with improvement of quality of life (QoL), reduced hot flahes. Time to 
hormone refractory state (HR) was statistically significantly improved on the IAS arm (Klotz 
et al., 2011).  
3.2 Essential drug, relatively cheaper and conventional systemic cancer drugs 
Fortunately, the pharmaceutical arsenal of "essential and conventional systemic anticancer 
drugs" still constitutes the basis of systemic treatment of cancer. In addition, these 
conventional drugs are relatively inexpensive. For breast cancer the list would include CMF 
(Cyclophosphamide, Methotrexate and 5 Fluorouracil), FAC (5 Fluorouracil, Doxorubicin 
and Cyclophosphamide), Tamoxifen and Ovarian ablation. Innovative strategic thinking 
and approaches should be encouraged to improve the availability and accessibility of first-
line systemic anticancer treatments as part of the comprehensive breast cancer control plan 
for underserved regions (Elzawawy, 2009). 
3.2.1 Is anthracycline-based chemotherapy standard as adjuvant breast cancer 
treatment? 
Six cycles of anthracycline-based chemotherapy was considered a standard in adjuvant 
treatment of breast cancer. However, there is data to suggest that not all patients will benefit 
from anthracyclines. In a recent study, patients who were Her2 negative did not gain any 
added benefit from addition of anthracylines as compared to regimens employing CMF 
(Cyclophosphamide, Methotrexate, and 5 Flourouracil) (Paik, 2008).  
3.2.2 Chemotherapy versus ovarian ablation as adjuvant breast cancer treatment 
Randomized studies over the past decade have demonstrated that ovarian 
ablation/suppression equivalence is at least equivalent to CMF regimens in receptor-
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positive premenopausal patients (Munshi, 2009). In a recent randomized study that 
included patients with large tumor sizes and nodal positivity, nine cycles of CMF were 
equivalent to RT-induced ovarian ablation. The study included 762 women who were 
premenopausal, were hormonal receptor positive, and were at high risk of relapse (defined 
as metastasis to at least one lymph node or tumor > 5 cm). The patients were randomized to 
receive either ovarian ablation by RT or chemotherapy with nine cycles of intravenous CMF. 
A total of 358 first events were observed: 182 in the ovarian ablation group and 176 in the 
CMF group. The unadjusted hazard ratio for disease-free survival in the ovarian ablation 
group compared with the CMF group was 0.99 (95% CI: 0.81 to 1.22; P = 0.95 by the log rank 
test). Median disease-free survival time was 130 months in the ovarian ablation group 
compared with 122 months in the CMF group. After a median follow-up of 10.5 years, the 
overall survival was similar in the two groups, with a hazard ratio of 1.11 (95% CI: 0.88 to 
1.42) for the ovarian ablation group compared with the CMF group. No significant 
correlation was demonstrated between treatment modality and hormone receptor content, 
age, or any of the well-known prognostic factors. This strategy may be considered in a low-
risk, young, premenopausal woman, whose compliance for chemotherapy is doubtful, and 
who has a strongly hormone-sensitive tumor. The readily apparent gains from this approach 
are that repeated visits for chemotherapy can be avoided, as also the toxicity of 
chemotherapy; there is also considerable savings in cost for the patient or the Medicare.  
(Ejlertsen, 2006). The ovarian ablation by radiotherapy could be done by simple technique, 
in 4-5 fractions, during or after the course of post mastectomy or lumpectomy radiotherapy 
to breast/chest wall. Also, it could be done by surgical ablation.  
3.3 The oral route for administration of chemotherapy 
The oral forms of chemotherapy could lower the cost of patient transportation, 
administration, hospitalizations, the subsequent costs of adverse effects of hospitalizations 
and it may improve the quality of life (Elzawawy, 2008 and Elzawawy, 2009). In fact, this 
point could be applied to old and new cancer drugs. More pharmacological and clinical 
researches as well as in manufacture of drugs are warranted. Hence, most known cancers 
could have regimes of treatment that are totally or partially administrated via oral route. 
The pros and cons of oral route administration of chemotherapy should be carefully studied 
in each community in a scientific and realistic ways. Questions of cost-effectiveness and best 
practices relating to oral and self-administered agents are of considerable interest in LMICs 
where facilities and providers may be particularly scarce. One of the major realistic obstacles 
is not the compliance, which should not be taken as an absolute and undefeatable problem 
in some population, but also, the factors related to oncologists and hospitals with less gain 
from oral therapy. In a win-win initiative all factors and interests of all stakeholders should 
be tackled in realistic, transparent, scientific and global ways.  
3.4 Genomics and cancer treatment 
Pharmacogenomics is the study of individual genetic variation in efficacy and adverse 
effects of a drug. Radiogenomics is reffered to the same science but for radiotherapy. This 
science offers a partial explanation for the interpatient variability in treatment response 
commonly observed in oncology. Small variations in patient germline DNA sequence 
(genotype), including single nucleotide polymorphisms (SNPs), can alter the expression and 
functional activity of an encoded protein. Often, genetic variants leading to clinically 
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relevant functional changes occur in noncoding (intron) regions of the genome or in exons 
that code for protein expression (Guttmacher& Collins, 2003). These changes may lead to 
individual differences in drug distribution, metabolism, activity and toxicity (Connolly& 
Stearns, 2009, Lash et. al, 2009).  
Pharmcogenomic studies were suggested to guide the adjustment the effective use of some 
drugs like Tamoxifen (Colleoni, 2002 & Lash, et al, 2009). Patients can be classified as poor, 
intermediate, or extensive metabolizers according to the genetic variation in CYP2D6, a key 
enzyme in Tamoxifen metabolism. In the poor metabloizers cases, the use of Tamoxifen, 
would be a waste of costs for 5 years of probably non sense treatment and with unnecessary 
risks of hazards. In the other hand, a modeling analysis suggested that the benefit of 5 years 
of adjuvant Tamoxifen therapy in patients who were carriers of the wild-type CYP2D6,the 
extensive metabolizers, was similar or perhaps superior when compared with the more 
expensive aromatase inhibitor therapy. Thus, it was suggested that onetime test for CYP2D6 
genotype has the potential to make the patient eligible for 5 years of savings by allowing for 
the use of -the less expensive- Tamoxifen (Punglia et al., 2007). However, more prospective 
studies about CYP2D6 and this topic are warranted, as recently there are controversies 
regarding the significance and value of the adoption of routine CYP2D6 testing in the clinic 
(Lash et al., 2009). Science is searching for the truth. The road for facts is endless and 
enjoyable. In fact, once again, not every exciting scientific finding could be translated into 
the same expected clinical value in the short and the long term clinical researches and trials 
(Elzawawy, 2010 & 2011).  
Besides probable different variations in human host and tumor biology, real local 
socioeconomic conditions and priorities of problem, cost effectiveness, cost utilty, available 
services including supportive treatment different, Pharmcogenomics and Radiogenomics 
are among the possible causes of that protocols and guidelines of treatment shouldn’t be 
copied in different communities without adaptation and without considering these factors 
in scientific and realistic ways.  
3.5 Generic equivalents for off-patent drugs  
The World Health Organization (WHO) proposed essential drugs required for cancer 
therapy (WHO, March 2010). Many drugs included in the ‘Essential Drugs for Cancer 
Therapy’ list have generic equivalents that offer the possibility of less expensive treatment. 
However, we stress on not taking the proposal of using generics off patent cancer drugs as a 
magic stick and automatically as an ideal solution for more cost effective treatment, without 
assuring the flow of production and the affordability of generics drugs of good quality. 
Particularly in developing countries, the quality and bioequivalence of generics drugs 
should be assured by regulations or developing a transparent system for international 
testing. A generic of good quality or an “original” essential drug would be more cost 
effective than generics of less quality, even if the later is of fewer prices. Also, the use of first 
line treatment of tested good quality drugs could reduce the needs for second and third 
lines treatment that are usually more expensive. Besides, the risk on patients, results of 
clinical trials and researches in LMICs would be doubtful if they are done with drugs with 
questionable quality. We suggested an international body or experts or programs that 
would assure the quality and bioequivalence of generics delivered to LMCIs. To overcome 
difficulties in achieving large scale feasibility in quality control, we suggested small scale 
groups level to test random samples or pilot settings upon invitation from the local 
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authorities in some developing countries. Hence, it wouldn’t be to police, but to advise and 
it would react only upon request from the locals (Elzawawy, 2008 & 2009). 
Contrary to belief, the availability of essential and generics off-patent cancer drugs is very 
critical issue to rich and developed countries and not only for developing countries. In 
November, 2010, the American Society of Clinical Oncology (ASCO) announced that across 
the United States, there is severe and worsening shortage of a big group of these drugs that 
are placing cancer patients in the US at risk, including –and not limited to- doxorubicin, 
carboplatin, cisplatin, etoposide, leucovorin, nitrogen mustard, vincristine and morphine. 
Michael Link, MD, president-elect of ASCO, for the term 2011-2012, said in a statement 
“Shortages of critical cancer drugs are causing delays in treatment, which can impact 
survival and the ongoing clinical trials. Additionally, administration of alternative therapies, 
if they are available, can lead to less optimal treatment, as well as increased costs, for 
patients and increased administrative burdens for oncology practices". Bona Benjamin, from 
the American Society of Health System Pharmacists (ASHP) stated “For hospital 
pharmacists, the shortage of injectable cancer drugs products — many of which have no 
therapeutic alternatives — is approaching a national crisis in the US. There is no single 
reason or solution for the shortages. Most of the cancer drugs that are in short supply are 
generic products and are manufactured by a few companies. There is no financial incentive 
to manufacture cheaper generic drugs. In a free market, there is nothing to compel 
manufacturers to make drugs that don't make them money; there is no hammer”. 
(Chustecka, 2010). One of the values of having global scientific approaches for the problems 
of availability and affordability of cancer is that we could explore and tackle proposals that 
could help –with variations- in developing and developed countries. The Win-Win initiative 
concentrates on scientific approaches that could lead finally to the benefit of all 
stakeholders.  
3.6 Old cancer drugs, new uses, news profits  
By scientific approaches, old cancer drugs could have new indications, and subsequently 
offering less expensive treatment to cancer. This implies exploring new indications or 
innovative combinations or different schedules of administration of older (and relatively 
cheaper) previously approved cancer. For example, the relatively old like cisplatin has been 
shown to be useful in the treatment of triple negative (-ve estrogen and progesterone 
receptors, HER2/neu 0, 1) breast cancer (Gronwald et al., 2009). The metronomic use of 
prolonged, low oral doses of the cheap drugs cyclophosphamide and methotrexate are used 
as palliative breast cancer treatment (Colleoni, 2002). In a recent phase II trial, the low dose 
(6 mg/d) oral estradiol was effective (around 30%) as conventional high dose (30 mg/d) 
with less adverse events in postmenopausal women with advanced, aromatase inhibitor-
resistant, hormone receptor-positive breast cancer (Ellis, 2009).  
3.7 Old non cancer drug, new uses in cancer, potential new profits 
An example is inexpensive drug called metformin. It's widely used by type 2 diabetics who 
overproduce insulin. But new researches suggest that it could be useful in breast cancer 
prevention and treatment. It was found that metformin can also act on lung cancer tumour 
growth in mice that have been exposed to a common carcinogen in cigarettes. Moreover, 
new studies suggest that it could be tested for colon cancer too. It's thought the drug works 
by targeting a cancer tumor's stem cells which, if not killed off, can allow various cancer cell 
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types to regenerate. Hence, have an old molecule, an old drug, a safe drug that may have an 
unexpected use in cancer prevention and cancer treatment. More studies are currently 
planned. Each tablet costs 21 cents and must be taken twice daily. Despite the low price, the 
cost to run such a clinical trial, which involves collecting blood samples, is expected to run 
at least $15-million. The trial is expected to include 3,582 patients in Canada and the United 
States who are undergoing standard cancer treatment plus metformin or placebo for up to 
five years. Until the results are in, patients should not use it unless it is prescribed for 
diabetes or they are on the clinical trial, where they can be properly monitored (Dowling, 
2011).  
3.8 New uses for cancer chemotherapy drugs in non malignant indications  
An example is the recent researches that revealed that fluorouracil could be used as a skin 
cream to help repair of sun damage and skin wrinkles on the faces. Topical fluorouracil 
causes epidermal injury, which stimulates wound healing and dermal remodeling resulting 
in improved appearance. The mechanism of topical fluorouracil in photoaged skin follows a 
predictable wound healing pattern of events reminiscent of that seen with laser treatment of 
photoaging (Sachs et al., 2009)  
4. Does evidence-based medicine really reduce costs? 
The question is paused by many from time to time. In a wonderful recent article the issue is 
discussed (Kolodzie, 2011). Till recently the issue was a theory and a hypothesis. It pass now 
to the phase of having proof. The adoption of pathways based on evidence-based medicine 
(EBM) in patients with non–small-cell lung cancer (NSCLC) revealed that evidence-based 
care resulted in an average cost-savings of 35% over 12 months and equivalent outcomes 
(Neubauer et al., 2010). It is important to note that not all pathways are created equal. Most 
programs use minimum criteria to develop their pathways; these typically include 
assessment of efficacy and toxicity. A few pathway programs go beyond these minimum 
criteria and consider costs as well. These types of programs delineate treatment options 
based on maximum survival benefits, minimal toxicity, and cost-saving advantages.  
4.1 Reduction in expensive supportive care drugs  
When two or more therapies are equally effective against a disease, regimens lower in 
toxicity are typically chosen to be on-pathway. This leads those physicians who adhere to 
pathways to be less likely to prescribe expensive anti-emetics, growth factors, and other 
supportive care drugs absent strong evidence to validate their use. 
4.2 Fewer hospital visits  
One of the most common reasons patients require hospitalization during treatment is 
adverse effects and complications caused by the agents. The less toxic on-pathway regimens 
can result in fewer or less severe adverse reactions, therefore reducing the number of 
unplanned hospital visits. 
4.3 Reduction in therapy overall  
Treatment guidelines, backed by evidentiary support, lead physicians to confidently 
recommend the most effective therapy as the first-line treatment with standard order sets 
www.intechopen.com
 
Science and Affordability of Cancer Drugs and Radiotherapy in the World - Win-Win Scenarios 
 
267 
that define dosing strengths and number of cycles. For many cancers, especially solid 
tumors in adults, each successive line of treatment is less efficacious than the preceding line. 
When patients with late-stage disease face difficult decisions, some will wish to continue a 
line of treatment no matter what. Others express the desire to improve their quality of life, 
with many stating that they prefer to die at home rather than in the hospital. (Wennberg et 
al., 2008). Third and fourth lines of treatments rarely change the course of the disease and 
can cause incapacitating adverse effects. More often than not, if a patient’s cancer has not 
responded to or has progressed after the first or second line of treatment, the best course for 
that patient may be to transition into end-of-life or palliative care. A study analyzing 
Medstat 2007 data in the US, revealed that out of those chemotherapy patients with 10 major 
cancer diagnoses who were identified as dying in an inpatient setting, 24% received 
chemotherapy within 14 days of death and 51% received chemotherapy within 30 days of 
death (Fitch & Pyenson, 2010). While we cannot always predict when death will occur, 
pathways can help guide physicians in making decisions and treatment recommendations 
pertaining to whether to offer additional cycles of a treatment or move to second, third, and 
further lines of treatment. They can also provide practical guidance that can be helpful in 
end-of-life care discussions. This includes demonstrating that transitioning to hospice care 
can improve the patient’s and the family’s quality of life and can reduce the costs borne by 
the family and payers by avoiding unnecessary and ineffective chemotherapy administered 
within a few weeks of death (Kolodzie, 2011).  
4.4 Use of less expensive drugs  
Oncology drug costs are exorbitant, making this line item an obvious target for payers as 
they search for ways to reduce costs. One way in which EBM can help reduce the costs of 
cancer care is by optimizing the appropriate use of less expensive drugs. When pathways 
are developed, it will often be found that evidence supports the use of less expensive 
therapies, without compromising outcomes or increasing toxicity. For example, if treatment 
pathways point to two potential therapies that are largely equivalent in efficacy and toxicity, 
yet these two drugs vary enormously in cost, pathways programs that consider cost a factor 
would ultimately point to the less expensive drug. Obviously, there are some cases in which 
cost cannot be a determining factor in deciding which drug to use to treat a patient. Where 
one therapy is far more effective than others, it is the clear choice and will be indicated as 
the first choice for that setting. Take trastuzumab as an example. Trastuzumab is 
unquestionably an expensive drug, but evidence for its efficacy in certain situations is 
indisputable. As pathways are developed, efficacy is given the highest priority, with cost 
being considered only when outcomes are equivalent. In the case of trastuzumab, the 
efficacy of the drug and the lack of available substitutes make it the correct choice- when it is 
used in appropriate indications- regardless of its price.  
5. Control of utilization of a drug as a primary strategy of Medicare, USA  
The primary strategy Medicare uses to hold down utilization of a drug (or another health 
care good or service) is to limit coverage of payment for it. The program does so by actively 
determining in which settings the drug is or is not "reasonable and necessary" through either 
a single national or one or more local coverage decisions. When these coverage decisions 
result in restricted guidelines for the use of the drug, the result is decreased utilization. For 
instance, in 2007, Medicare narrowed the coverage of erythropoiesis-stimulating agents 
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(ESAs) for cancer treatment. Medicare limited not only the types of patients who could 
receive ESAs but also the clinical scenarios in which they could be used (Centers for 
Medicare & Medicaid Services, 2007). One of the biggest companies who sale ESAs in the 
USA, reported to their investors in August 2007 that changes in coverage for ESAs by the 
Centers for Medicare and Medicaid Services (CMS) would reduce annual sales of the 
company's ESA from approximately $1 billion to $200 million among Medicare patients. In 
our view, the lesson here, is that if the strategy of control utilization is indicated in a rich 
country like the USA, then, it would be mandatory in less affluent countries. In a win-win 
scenarios, our objective is not at all against the sales of drugs per se, but this strategy of 
controlling utilization of drugs, by whatever the mechanism in each country, would assure 
more reasonable and justified utilization of drugs (or services). Otherwise, the chaos in its 
utilizations in some less affluent countries, opens wide doors for the use of these drugs 
when it is not necessary while omitting patients who are in real big need for these drugs, for 
more local corruptions and exhausting resources in non cost effective ways without marked 
improvement of outcome and in non cost effective ways, and finally it could lead to collapse 
of markets in those of countries in front of new products of companies. Hence, transparent 
scientifically based measures are encouraged by the win-win initiative for the benefit  of all 
stakeholders. 
6. Economic analyses and outcomes assessment  
Economic analyses are most valuable to health policy analysis and health care managers 
who must allocate resources and established health care management. An economic 
health care analysis tries to directly relate the incremental cost of an intervention to its 
potential benefit. (Hayman et al., 1996). Clinical Oncologists shouldn’t be away from 
knowing basic information and various terms of such issues. That is why –at least the 
definitions- are included in many cancer treatment textbooks or in chapters dealing with 
availability, accessibility and affordability of cancer treatment. Not surprisingly, high 
costs can be financially devastating to American patients and their families, with some 
62% of all bankruptcies estimated to result from medical expenses (Himmelstein et al, 
2009). The American Society of Clinical Oncology (ASCO) has issued a Guidance 
Statement affirming "the critical role of oncologists in addressing cost of care" and stating 
that "ASCO believes that communication with patients about the cost of care is a key 
component of high-quality care (Meropol et al.,2009). However, many oncologists feel ill-
prepared to discuss the costs of therapy with patients, (Schrag &Hange, 2007) and little is 
known about how patients factor cost into their decision-making when facing a life-
threatening crisis of a cancer diagnosis (Mileshkin, 2009). 
6.1 Definitions of various terms used in economic analysis  
6.1.1 Cost minimization  
It relates to lower cost of an alternative treatment without regard to the efficacy. It is measured 
in dollars. The major drawback of only using this approach to evaluate cancer treatment is the 
fact that complex-oncology therapies almost never result in truly identical outcomes.  
6.1.2 Cost benefit  
It relates to the additional cost of treatment in dollars to its incremental benefit in dollars, as 
compared to the most reasonable alternative treatment. Results of cost benefit analyses also 
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can be reported as a ratio, where the additional cost of treatment is divided by its added 
benefit, again compared to the most reasonable alternative.  
6.1.3 Cost effectiveness  
It relates the additional costs of an intervention to its incremental impact on any clinically 
relevant measure of benefit. Because one of the primary uses of economic analysis is the 
allocation of limited resources among different choices, benefit often is measured in units 
that are universally applicable to all intervention. Years of life saved are the most commonly 
used measure. For example, the cost-effectiveness of combination chemotherapy, compared 
with single-agent therapy, for a given disease could be assessed by calculating the 
additional costs (in dollars or the monetary units) per additional patient reaching the 5-year 
disease-free survival mark or more frequently, per years of life saved.  
The Incremental cost-effectiveness ratio (ICER) or The intervention’s cost-effectiveness ratio 
is calculated by dividing its incremental cost by its incremental impact on survival, as 
compared to the most reasonable alternative treatment. The intervention’s cost-effectiveness 
ratio, expressed in units of dollars per unit of effect compared to the standard intervention. 
Years of life saved are the most frequently used measure. Cost-Effectiveness ratios are, 
therefore, usually expressed in terms of dollars per year of life saved.  
6.1.4 The QALY and the DALY  
Medical interventions affect not only length of life but also quality of life (QoL). Cancer cure 
may be brought at the expense of substantial treatment-related morbidity. Conversely, 
palliative therapy may bring marked relief of symptoms; even it does not lengthen life 
dramatically. A nonmonetary unit for evaluation is the quality – adjusted life year (QALY). 
QALY measure the “usefulness “or “utility” of a health state and the length of life lived under 
those conditions. One attempts to obtain values or utility measures by expert opinion, by using 
values derived in previous studies, and by surveys of patients. These surveys can be difficult 
to construct and may involve asking patients to make a “time tradeoff“ or engage in a “rating 
scale “of various conditions or to assign a preference weight on a scale of 0 to 1 to a condition. 
The DALY is the disability-adjusted life year. WHO has suggested that a health intervention 
can be considered cost effective if it yields savings of one disability-adjusted life year for less 
than three-times a country’s gross domestic product (GDP) (Torres Edejer et al., 2003).  
6.1.5 Cost utility  
It relates the additional cost of treatment to its impact on both survival and quality of life, as 
well as productivity of the patient following treatment. The length of time spent in each 
outcome is multiplied by the outcome’s weighting factor and the product is summed. A 
cost-utility analysis may be considered as special form of a cost-effective analysis. In the 
cost-utility analysis, the health outcome of the denominator is valued in term of utility or 
quality of life. The monetary units of evaluation include the QALY. It is common to express 
cost-utility analysis as total net cost per unit of utility or measure of quality – for example, a 
number of dollars or saving per QALY gained. A cost-utility ratio can be calculated by 
dividing its additional cost by its incremental change in QALYs, compared to a reasonable 
alternative. Hence, the units of the cost-utility ratio is Dollars/QALY.  
We can conclude that over the past decade it has become increasingly clear that, in addition 
to quantity of life, the impact of treatment on quality of life must be incorporated into 
measures of benefit. (Hayman et al., 1996 & Weeks, 2003).  
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It worthwhile to note that the “no treatment” strategy does not necessarily mean it is a “no 
cost “strategy. Hence, in our view, contrary to belief, the affordability of well-tailored 
scientifically based treatment or appropriate palliation could -in many cases- reduce 
variable costs and burden of “no treatment”. We hope that this message finds its way to 
local leaders of health policies decisions makers, leaders of global health departments in the 
world and in the United Nations Non Communicable Diseases (NCDs) meetings.  
7. Health technology assessment (HTA) programs  
HTA programs evaluate the value of new therapies and technologies to patients by 
considering the following (Hutton et al, 2006): Is the new treatment effective? Although 
surrogate end points such as response rate may be sufficient evidence of efficacy for 
regulatory agencies (eg, rise in hemoglobin after administration of erythropoietin 
stimulating agent), HTAs generally demand more direct evidence of benefit (eg, improved 
quality of life measured by a validated instrument, or improved survival). Which patients 
benefit? If the clinical trial population excluded particular patient populations, are they 
likely to have the same benefit as the patients included in the study? How does it compare to 
other available treatments? At what cost?  
Many countries now incorporate HTAs into their decision-making process before deciding 
to cover new therapies within their publicly funded health care systems. The United 
Kingdom was the first country to adopt HTA explicitly by creating the National Institute for 
Clinical Effectiveness in 1999. Since then, many other countries, including Australia, 
Belgium, Canada, Denmark, Finland, German, Hungary, the Netherlands, Norway, 
Portugal, and Sweden, have developed processes for HTA to be used in coverage decisions. 
Although to date the information does not appear to have had much impact on formulary 
decisions, US private health plans are increasingly requesting pharmaceutical manufacturers 
to submit evidence dossiers that adhere to the Academy of Managed Care Pharmacy 
guidelines and include information on clinical and cost effectiveness (Sullivan et al., 2009)  
8. Finally, we emphasize on these points  
To enhance researches and scientific studies that result in decreasing the total cost of treatment 
and to increase –or at least not to compromise- effectiveness and quality of life. It is preferred 
to design -as most as possible- protocols of treatment that require less or no hospitalizations-
except in some cases, less costs of auxiliary cares and expensive supportive drugs that could be 
not available in the community or it could produce high additional financial burden.  
To develop more scientific researches that go with the notion of “Resource-level-appropriate 
use of costly agents” and that necessarily involves inclusion of how to mobilize the locally-
available resources and the establishment of viable partnerships with different sectors in the 
community. Hence, LMICs  shouldn’t  count on financial donations from far, as they would 
be never enough. The real lasting help to these communities is in assisting of local capacity 
building, for cooperative scientific researches, training, assistance in reporting and 
publications and appropriate technology transfer.  
To test innovative combinations or different schedules of administration of older (and 
relatively cheaper) drugs that might lead to improve therapeutic index or newer 
applications in different societies. Such investigations usually are not supported by 
pharmaceuticals companies and international conferences, although they might be of benefit 
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to science and cancer patients in LMICs and affluent countries. Conducting such researches 
in LMICs would be a sort of capacity building for researches and clinical trials that could be 
used for conducting trials with appropriate ethical guidelines - and subsequent access - for 
newer drugs in these communities and it could pave the ways for justified use and sales of 
newer drugs in more cost effective ways in markets that risk to shrink in the upcoming 
years. Such approach would assist companies in streamlining the development of new 
drugs and technologies. 
To disseminate the concept of global and balanced cancer control including earlier diagnosis 
and supportive and palliative care. Earlier diagnosis of less advanced cases could decrease 
the total costs of treatment and increase quality of life. But, screening and efforts for early 
detection without having affordable treatments that respect what we call “The economic 
and social dignity of patients and their families” would be fruitless and it would be 
frustrating for both patients and health professionals. (Elzawawy et al., 2008). Incidence of a 
particular cancer, total per-capita health spending (WHO, 2010), country’s gross domestic 
product (GDP) should be considered in estimation cost-effectiveness of some screening 
programs like mammographic screening for breast cancer. Resources in LMCs might be 
better used to raise awareness and encourage more women with palpable breast lumps to 
seek and receive treatment in a timely manner and to assure patient navigator services in 
LMCs, which aim to help women access their health-care system and receive better care 
once in the system, could be more cost effective than attempts to screen the asymptomatic 
masses (Harford, 2011). Palliative care is an essential component of comprehensive cancer 
care (Becker et al., 2011). The availability of supportive and palliative care integrated 
oncology could improve outcome, reduce overall costs, lessen burden on patients and 
families and improve qualities of life and death.  
Thinking is never enough. We have two preliminary proposals and we cite them here as 
questions for wider discussion. We suggest the term: “The Relevant Clinical Oncology”. It 
considers the variability in biologic and pharmacologic factors among the human hosts 
and the nature of tumors, cost effectiveness and cost utility as well as the real 
socioeconomic conditions. It respects the expectations and priorities of the human beings 
of each community (A. Elzawawy, 2011). Moreover, we see that the term “personalized” 
or “customized” cancer treatment is usually concentrated on hitting one or more 
biological targets that could varied from a tumor to another. We proposed to extend this 
term to include more aspects of the human host like variability in pharmcogenomics, 
pharmcodynamics and pharmacokinetics for different drugs, and other personal 
variations in human beings like socio-economic aspects. Hence, we hope that in the 
future, the term personalized treatment would pass from “The mechanics” of hitting one 
target in the tumor by a drug, to the more broader concept and vision of medicine to 
consider biological tumor factors, human factors and medical wisdom without 
compromising the overall outcome and via evidence based researches and trials. It is a 
real challenge. (Elzawawy,2011).  
There is a question raised recently in the USA “We have a choice: do we use science to help 
us reach consensus on what we are willing to pay for new therapies and innovation, or do 
we leave individual patients to wrestle with the skyrocketing costs of cancer care and 
treatment determined by their ability to pay?”(Malin, 2010). And globally, we raise the 
question, are we going to see innovation in cancer treatment and drugs as a of complicating 
problems of its affordability or we will use science to lessen this rising problem as it 
facilitates many things in our daily life?.  
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9. Conclusion  
There are no indications that the costs of the novel cancer drugs and radiotherapy of cancer 
and the incidence and prevalence of cancer will stop increasing in the next decade. Hence, 
there would be more difficulties and challenges for patients, families, governments, 
physicians, manufacturers of cancer drugs and radiotherapy equipment, particularly in Low 
and Middle Income Countries (LMICs). However, there are also increasing concerns in 
affluent countries and the USA about the increasing costs of cancer therapy. Starting from 
December 2007, with communications, publications and working meetings, the win-win 
initiative was proposed by ICEDOC’s Experts in Cancer without Borders (ICEDOC: is the 
International Campaign for Establishment and Development of Oncology Centers 
www.icedoc.org). The win-win initiative stress on the scientific approaches and in 
considering stakeholders in win-win scenarios in which no one would lose. Our concerns is 
to lower the total costs (not necessarily the price of a drug or an equipment), to flourish the 
system and save it from risk of collapse. In this chapter, we reviewed examples of the 
recently published scientific works that could lead to lower the overall costs of breast cancer 
radiotherapy and systemic chemotherapy and hormonal treatment without compromising 
patients' outcomes. It is presented as a model, to be expanded to other cancers. The cited 
approaches, with our views, are not presented as wholly inclusive or definitive solutions but 
are offered as effective examples and as stimuli to hopefully inspire the development of 
more evidence based management approaches that provide cost effective and more 
affordable cancer treatment. We recommend to adopt win-win scenarios and to create what 
Franklin D Roosevelt described as “A Brain Trust” opened for innovative scientific 
thoughts, ideas and strategies, to foster relevant scientific researches and collaboration that 
would aim at achieving cost-effective and accessible cancer treatment for more millions of 
patients with cancers in the world. The win-win initiative is an open movement and it is 
inspired from the works and publications of many scientists. We don’t claim patency. The 
key leaders of international oncology community and organizations are sharing in the 
development of the initiative and its working meetings. Hence, it is a concept and an 
approach that we call all for cooperation for its wide dissemination, to be adopted and to be 
owned by all who are concerned in the upcoming years. We emphasize on the importance of 
considering the broad sense for the term science and not to be taken as just to copy the 
imported protocols or guidelines of treatment. Hence, scientific cooperation, exchange of 
experiences, customized clinical trials and treatment that respect the realistic biological, 
human, social and economic conditions, cost -effectiveness, quality of life cost -utility and 
adapted to each community are recommended. Despite that, the motivation of this initiative 
is largely humanitarian, but it is based on scientifically derived evidence and reflects ‘win-
win’ scenarios for global cancer management. 
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